Edimer is a biotech company founded in 2008 and based in Cambridge US focusing on the development of innovative therapeutics for rare diseases. EDI 200 Fc-EDA1, its lead product is aimed at the treatment of X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare inherited genetic disease affecting mainly baby boys. Moreover, Fc-EDA1 is in development for Read the full article…
Deal United creates incremental revenue for merchants by converting non-buying customers into buying customers. This way, merchants can leverage their existing website traffic without additonal costs. Customers who accept an offer by one of Deal United’s partners get the merchant´s product for free. The company has been sold.
Covalys’ proprietary technology is based on unique protein tags (SNAP-, CLIP-, ACP/MCP-tags) which would greatly facilitate the purification, labeling and immobilization of proteins in their functional form, opening thus new opportunities for protein based research. Covalys’ tag technology combines specificity with high reliability, stability and a broad versatility in its applications. Covalys’ tag technolgy was Read the full article…
The CeQur PaQ™ insulin delivery device is intended for continuous, subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in patients requiring insulin as prescribed by a physician. The technology is reliable, the design had met high industry standards and the IP situation (patentability and freedom to operate) is Read the full article…
Cell Medica is committed to improving patients’ lives through the significant therapeutic potential of cellular immunotherapy. Our approach is to apply innovative technologies with the aim of improving the treatment of cancer and immune reconstitution following hematopoietic stem cell transplant. VI became shareholder of Cell Medica through its acquisition of Delenex Therapeutics. Delenex was a Read the full article…
Avalon Photonics AG is a leader in the manufacturing of semiconductor based lasers (vcsel’s). It produces amongst other lasers the key optical component of most laser based navigation mouse sold on the market presently. Avalon was acquired in 2006 by Bookham for approx. USD 5.5m in Bookham stock. In the meantime, Bookham has merged with Read the full article…
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on a on a novel antibody-drug conjugate (ADC)-linker technology. ADCs deliver for example chemotherapeutic drugs specifically to the tumor and thus enable targeted chemotherapy. The stable and defined linkage of the drug to the antibody is essential for Read the full article…
Amal Therapeutics SA is a spin-off from the University of Geneva. Amal develops KISIMA, its proprietary vaccine technology platform to progress therapeutic vaccines in oncology. KISIMA combines in one single recombinant protein a vector for targeted antigen delivery, a toll like receptor peptide agonist as adjuvant and a chimeric multi-antigenic construct as vaccine. The platform Read the full article…
Based on 12 years of R&D and clinical trials with more than 2500 patients, Altoida has developed complex everyday activities providing neuromotor biomarkers that can diagnose Alzheimer’s disease 5 years prior to onset with 94% accuracy using smartphones and augmented reality. Altoida’s technology will power apps that target both consumer and professionals markets. Learn more Read the full article…
Advanon is an online platform where SMEs looking for short-term financing can sell their invoices to financial Investors. Through the easy-to-use platform, SMEs can improve their cash balance instantly. Investors, on the other hand, get access to an alternative type of short-term investments. Unlike traditional factoring services that acquire all invoices from a seller Advanon is offering a flexible service as businesses can sell invoices when and as they need it.
Activaero is the global technology leader in controlled breathing technologies for inhaled therapeutics. With approved, stand alone inhalation products and inhalation systems available for clinical trials and marketing partnerships, Activaero’s technologies allow for the most precise and efficient patient-tailored pulmonary delivery.
Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, today announced it has received an additional CHF 12.7 million in seed financing, bringing the total amount raised to CHF 15.2 million.
Ghent, Belgium – 22 October 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces positive interim results from the first five patients enrolled in the RED DESERT study, evaluating repeated dose treatment of alfapump DSR (Direct Sodium Removal) in diuretic-resistant heart failure patients. Sequana Medical also provides a business update.
Madrid, Spain, October 6th 2020:
Medlumics, which develops Ablaview®, a unique RF irrigated ablation catheter system that merges photonics and miniaturized optics to guide device placement and directly assess the ablation lesions in real time, announces today the closing of a €14 million Series E financing, co-led by Asabys Partners (through the fund Sabadell Asabys Health Innovation Investments), VI Partners and CDTI Innvierte, with the participation from historical investors Andera Partners, Caixa Capital Risc and Innogest Capital. Several of the investors joining this round were investors in Endosense, a company in the same space acquired by Abbott (St. Jude Medical) in 2013 for more than USD 300 million.
Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX therapies, announces today further progress in two investigator-initiated Phase II trials of setanaxib in diabetic kidney disease (DKD) and idiopathic pulmonary fibrosis (IPF).
JenaValve Technology, Inc., a developer of a novel transcatheter aortic valve replacement (TAVR) system for the treatment of aortic valve disease, today announced the appointment of two veteran medical device executives Vinny Podichetty, MD, MS as Vice President, Clinical Affairs, and Jeff Thiel as Vice President, Operations, effective immediately.
